PMID- 38347911
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240214
IS  - 1178-7007 (Print)
IS  - 1178-7007 (Electronic)
IS  - 1178-7007 (Linking)
VI  - 17
DP  - 2024
TI  - Fecal Microbiota Transplantation: A Prospective Treatment for Type 2 Diabetes 
      Mellitus.
PG  - 647-659
LID - 10.2147/DMSO.S447784 [doi]
AB  - PURPOSE OF REVIEW: The aim of this review is to summarize the role of 
      gastrointestinal microbiome (GM) in the development of type 2 diabetes mellitus 
      (T2DM). Besides, we discuss the feasibility of applying FMT in the treatment of 
      T2DM and propose a series of processes to refine the use of FMT in the treatment 
      of T2DM. RECENT FINDINGS: T2DM is a metabolic disease which is connected with the 
      GM. According to many researches, GM can produce a variety of metabolites such as 
      bile acid, short chain fatty acids, lipopolysaccharides and trimethylamine oxide 
      which play an important role in metabolism. FMT is a method to regulate GM and 
      has been observed to be effective in the treatment of metabolic diseases such as 
      T2DM in some mouse models and people. However, there is still a lack of direct 
      evidence for the use of FMT in the treatment of T2DM, and the process of FMT is 
      not standardized. SUMMARY: Dysregulation of GM is closely related to the 
      development of T2DM. Promoting the conversion of GM in T2DM patients to normal 
      population through FMT can reduce insulin resistance and lower their blood 
      glucose level, which is an optional treatment for T2DM patients in the future. At 
      present, the feasibility and limitations of applying FMT to the treatment of T2DM 
      need to be further studied.
CI  - (c) 2024 Zhou et al.
FAU - Zhou, Xiaolan
AU  - Zhou X
AD  - Department of Endocrinology, Hospital of Chengdu University of Traditional 
      Chinese Medicine, Chengdu, People's Republic of China.
FAU - Chen, Rumeng
AU  - Chen R
AD  - School of Life Sciences, Beijing University of Chinese Medicine, Beijing, 
      People's Republic of China.
FAU - Cai, Yichen
AU  - Cai Y
AD  - Department of Endocrinology, Hospital of Chengdu University of Traditional 
      Chinese Medicine, Chengdu, People's Republic of China.
FAU - Chen, Qiu
AU  - Chen Q
AD  - Department of Endocrinology, Hospital of Chengdu University of Traditional 
      Chinese Medicine, Chengdu, People's Republic of China.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20240208
PL  - New Zealand
TA  - Diabetes Metab Syndr Obes
JT  - Diabetes, metabolic syndrome and obesity : targets and therapy
JID - 101515585
PMC - PMC10860394
OTO - NOTNLM
OT  - fecal microbiota transplantation
OT  - gastrointestinal microbiome
OT  - treatment
OT  - type 2 diabetes mellitus
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2024/02/13 06:45
MHDA- 2024/02/13 06:46
PMCR- 2024/02/08
CRDT- 2024/02/13 03:35
PHST- 2023/11/01 00:00 [received]
PHST- 2024/01/23 00:00 [accepted]
PHST- 2024/02/13 06:46 [medline]
PHST- 2024/02/13 06:45 [pubmed]
PHST- 2024/02/13 03:35 [entrez]
PHST- 2024/02/08 00:00 [pmc-release]
AID - 447784 [pii]
AID - 10.2147/DMSO.S447784 [doi]
PST - epublish
SO  - Diabetes Metab Syndr Obes. 2024 Feb 8;17:647-659. doi: 10.2147/DMSO.S447784. 
      eCollection 2024.